System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD79a

HM57 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-530-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-530-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-530-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-530-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
  1A-530-T025 APC 25 tests yes choose region PDF datasheetHTML datasheet buy
  1A-530-T100 APC 100 tests yes choose region PDF datasheetHTML datasheet buy
  1Y-530-T025 PE-Dyomics 647 25 tests yes choose region PDF datasheetHTML datasheet buy
  1Y-530-T100 PE-Dyomics 647 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD79a (Ig alpha, MB1) forms disulfide-linked heterodimer with CD79b (Ig beta). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Specificity

The antibody HM57 interacts with CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.
HLDA V; WS Code BC cB018
HLDA VI; WS Code BP 193
HLDA VI; WS Code BP 89
HLDA VI; WS Code B B103
HLDA VI; WS Code B CD79.4

Immunogen

Synthetic peptide corresponding to amino acids 202-216 of human CD79a

Species Reactivity:

  • Human
  • Porcine
  • Mouse
  • Rat
  • Bovine
  • Equine (Horse)
  • Rabbit
  • Guinea pig
  • Opossum
  • Chicken
  • Other not determined

Negative Species:

Applications:

  • Flow Cytometry
  • Immunohistochemistry (paraffin sections)
  • Immunohistochemistry (frozen sections)
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

  • *Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe J.G.: Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001 Dec 3;194(11):1583-96. [Abstract] [Full Text]
  • *Pike KA, Iacampo S, Friedmann JE, Ratcliffe M.J.: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol. 2004 Feb 15;172(4):2210-8. [Abstract] [Full Text]
  • *Fuentes-Pananá EM, Bannish G, Shah N, Monroe J.G.: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11. [Abstract] [Full Text]
  • *Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe J.G.: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52. [Abstract] [Full Text]
  • *Fuentes-Pananá EM, Bannish G, Karnell FG, Treml JF, Monroe J.G.: Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol. 2006 Dec 1;177(11):7913-22. [Abstract] [Full Text]
  • Product Specific References

  • *van Noesel CJ, van Lier RA, Cordell JL, Tse AG, van Schijndel GM, de Vries EF, Mason DY, Borst J.: The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene. J Immunol. 1991 Jun 1;146(11):3881-8. [Abstract]
  • *Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al.: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1;147(11):2474-82. [Abstract]
  • *Mason DY, van Noesel CJ, Cordell JL, Comans-Bitter WM, Micklem K, Tse AG, van Lier RA, van Dongen J.J.: The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. Eur J Immunol. 1992 Oct;22(10):2753-6. [Abstract]
  • *Jones M, Cordell JL, Beyers AD, Tse AG, Mason D.Y.: Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J Immunol. 1993 Jun 15;150(12):5429-35. [Abstract]
  • *Mason DY, Cordell JL, Brown MH, Borst J, Jones M, Pulford K, Jaffe E, Ralfkiaer E, Dallenbach F, Stein H, et al: CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood. 1995 Aug 15;86(4):1453-9. [Abstract]
  • *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
  • *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
  • *Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross-reactive anti-human monoclonal antibodies as a tool for B-cell identification in dogs and pigs. Vet Immunol Immunopathol. 2007 Sep 15;119(1-2):56-62. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Related Products

  • Mouse IgG1 Isotype Control
  • Example Data

    HM57
    Fig. 1.


    Fig. 1. Intracellular staining of CD79a with anti-CD79a (HM57) PE (gated on leukemic blast cells) in a patient with childhood B-precursor ALL.

    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy